These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. ¹⁸F-FDG-PET/CT in staging, restaging, and treatment response assessment of male breast cancer. Groheux D; Hindié E; Marty M; Espié M; Rubello D; Vercellino L; Bousquet G; Ohnona J; Toubert ME; Merlet P; Misset JL Eur J Radiol; 2014 Oct; 83(10):1925-33. PubMed ID: 24985086 [TBL] [Abstract][Full Text] [Related]
30. Use of (18)F-FDG PET/CT in the preoperative evaluation of patients diagnosed with peritoneal carcinomatosis of ovarian origin, candidates to cytoreduction and hipec. A pending issue. Lopez-Lopez V; Cascales-Campos PA; Gil J; Frutos L; Andrade RJ; Fuster-Quiñonero M; Feliciangeli E; Gil E; Parrilla P Eur J Radiol; 2016 Oct; 85(10):1824-1828. PubMed ID: 27666623 [TBL] [Abstract][Full Text] [Related]
31. Multiple primary malignant tumors of upper gastrointestinal tract: a novel role of 18F-FDG PET/CT. Sun L; Wan Y; Lin Q; Sun YH; Zhao L; Luo ZM; Wu H World J Gastroenterol; 2010 Aug; 16(31):3964-9. PubMed ID: 20712059 [TBL] [Abstract][Full Text] [Related]
32. Whole-body FDG-PET in patients with stage I non-seminomatous germ cell tumours. Lassen U; Daugaard G; Eigtved A; Højgaard L; Damgaard K; Rørth M Eur J Nucl Med Mol Imaging; 2003 Mar; 30(3):396-402. PubMed ID: 12634968 [TBL] [Abstract][Full Text] [Related]
33. Does positron emission tomography using 18-fluoro-2-deoxyglucose improve clinical staging of testicular cancer?--Results of a study in 50 patients. Cremerius U; Wildberger JE; Borchers H; Zimny M; Jakse G; Günther RW; Buell U Urology; 1999 Nov; 54(5):900-4. PubMed ID: 10565755 [TBL] [Abstract][Full Text] [Related]
35. Prognostic Importance of Bone Marrow Uptake on Baseline Soydal C; Koksoy EB; Yasar A; Turgal E; Erdogan BD; Akbulut H; Kucuk NO Cancer Biother Radiopharm; 2016 Dec; 31(10):361-365. PubMed ID: 27996313 [TBL] [Abstract][Full Text] [Related]
36. Clinical value of Caspersen KB; Giannoutsou N; Gerke O; Alavi A; Høilund-Carlsen PF; Hess S Ann Nucl Med; 2019 Mar; 33(3):184-192. PubMed ID: 30569441 [TBL] [Abstract][Full Text] [Related]
37. ¹⁸F-Fluorodeoxyglucose positron emission tomography/computed tomography finds answers in cancer patients with increasing tumor markers and negative or equivocal conventional imaging modalities. Salem SS; Shahin MA Nucl Med Commun; 2012 Mar; 33(3):313-21. PubMed ID: 22237387 [TBL] [Abstract][Full Text] [Related]
38. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. Gayed I; Vu T; Iyer R; Johnson M; Macapinlac H; Swanston N; Podoloff D J Nucl Med; 2004 Jan; 45(1):17-21. PubMed ID: 14734662 [TBL] [Abstract][Full Text] [Related]
39. [Comparison of 18F-FDG coincidence SPECT imaging and computed tomography in the initial staging and therapeutic evaluation of lymphomas]. Qiao WL; Zhao JH; Wang C; He ZY; Wang TS; Xing Y Zhonghua Zhong Liu Za Zhi; 2007 Jul; 29(7):536-9. PubMed ID: 18069637 [TBL] [Abstract][Full Text] [Related]
40. Whole-body Gajjala SR; Hulikal N; Kadiyala S; Kottu R; Kalawat T Indian J Med Res; 2018 Mar; 147(3):256-262. PubMed ID: 29923514 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]